FDA’s 2022 Drug Approvals

The year 2022 was a good, but perhaps not great year for innovation. According to the FDA’s Center for Drug Evaluation and Research’s (CDER) New Drug Therapy Approvals 2022 report, there were 37 novel drugs approved in 2022. This number is down from the historical rate of approvals between 2013-2021 (43.4 approvals per year) and…

The evolution of PBMs over the past 2 decades

A ViewPoint by Richman and Adashi in JAMA this week provides a nice overview of the pharmacy benefit manager (PBM) marketplaces as well as some considerations for the Federal Trade Commission (FTC) to consider.  Below I summarize some of the developments in the PBM market in recent decades. Of particular note is that PBMs have…

Impact of medication cost-sharing on adherence, clinical outcomes, health care utilization, and costs

This is the paraphrased title of a paper by Fusco et al. (2023). The authors conduct a systematic literature review of studies published between 2010 and 2020 and find that among the 79 articles screened: The majority of publications found that, regardless of disease area, increased cost-sharing was associated with worse adherence, persistence, or discontinuation.…